Triple therapy for RA now approved for EAP

The Exceptional Access Program has decided to accept failure of 3 months of  standard triple therapy (MTX 20 mg qweekly, Sulfasalzine 2 gm/day and Plaquenil 400 mg daily) as equivalent to failure of 3 months of methotrexate 20 mg qweekly plus leflunomide 20 mg daily to access EAP-funded biologic drugs. Full details can be accessed here.